Search Results - "David Roodman, G."

Advances in the biology and treatment of bone disease in multiple myeloma by Raje, Noopur, Roodman, G David

“…Osteolytic bone disease is pathognomonic of multiple myeloma (MM) and affects more than 80% of patients. Bone disease results in skeletal-related events (SRE)…”
Get full text

Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma by Delgado-Calle, Jesus, Anderson, Judith, Cregor, Meloney D, Hiasa, Masahiro, Chirgwin, John M, Carlesso, Nadia, Yoneda, Toshiyuki, Mohammad, Khalid S, Plotkin, Lilian I, Roodman, G David, Bellido, Teresita

“…In multiple myeloma, an overabundance of monoclonal plasma cells in the bone marrow induces localized osteolytic lesions that rarely heal due to increased bone…”
Get full text

Multiple myeloma bone disease: pathophysiology of osteoblast inhibition by Giuliani, Nicola, Rizzoli, Vittorio, Roodman, G. David

“…Multiple myeloma (MM) is a plasma cell malignancy characterized by a high capacity to induce osteolytic bone lesions. Bone destruction in MM results from…”
Get full text

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update by Anderson, Kenneth, Ismaila, Nofisat, Flynn, Patrick J, Halabi, Susan, Jagannath, Sundar, Ogaily, Mohammed S, Omel, Jim, Raje, Noopur, Roodman, G David, Yee, Gary C, Kyle, Robert A

“…Purpose To update guideline recommendations on the role of bone-modifying agents in multiple myeloma. Methods An update panel conducted a targeted systematic…”
Get full text

Bone Pain Induced by Multiple Myeloma Is Reduced by Targeting V-ATPase and ASIC3 by Hiasa, Masahiro, Okui, Tatsuo, Allette, Yohance M, Ripsch, Matthew S, Sun-Wada, Ge-Hong, Wakabayashi, Hiroki, Roodman, G David, White, Fletcher A, Yoneda, Toshiyuki

“…Multiple myeloma patients experience severe bone pain (MMBP) that is undertreated and poorly understood. In this study, we studied MMBP in an intratibial mouse…”
Get full text

EZH2 or HDAC1 Inhibition Reverses Multiple Myeloma-Induced Epigenetic Suppression of Osteoblast Differentiation by Adamik, Juraj, Jin, Shunqian, Sun, Quanhong, Zhang, Peng, Weiss, Kurt R, Anderson, Judith L, Silbermann, Rebecca, Roodman, G David, Galson, Deborah L

“…In multiple myeloma, osteolytic lesions rarely heal because of persistent suppressed osteoblast differentiation resulting in a high fracture risk. Herein,…”
Get full text

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease by TERPOS, Evangelos, MORGAN, Gareth, REIMAN, Tony, JURCZYSZYN, Artur, MERLINI, Giampaolo, SPENCER, Andrew, LELEU, Xavier, CAVO, Michele, MUNSHI, Nikhil, VINCENT RAJKUMAR, S, DURIE, Brian G. M, ROODMAN, G. David, DIMOPOULOS, Meletios A, DRAKE, Matthew T, LENTZSCH, Suzanne, RAJE, Noopur, SEZER, Orhan, GARCIA-SANZ, Ramón, SHIMIZU, Kazuyuki, TURESSON, Ingemar

“…The aim of the International Myeloma Working Group was to develop practice recommendations for the management of multiple myeloma (MM) -related bone disease…”
Get full text

A novel role of IL-17–producing lymphocytes in mediating lytic bone disease in multiple myeloma by Noonan, Kimberly, Marchionni, Luigi, Anderson, Judy, Pardoll, Drew, Roodman, G. David, Borrello, Ivan

“…Osteoclast (OC)–mediated lytic bone disease remains a cause of major morbidity in multiple myeloma. Here we demonstrate the critical role of…”
Get full text

Regulation of Osteoclast Differentiation by ROODMAN, G. DAVID

“…:  The osteoclast (OCL) is derived from the cells in monocyte‐macrophage lineage. The earliest identifiable OCL precursor is the granulocyte‐macrophage…”
Get full text

Increased S1P expression in osteoclasts enhances bone formation in an animal model of Paget's disease by Nagata, Yuki, Miyagawa, Kazuaki, Ohata, Yasuhisa, Petrusca, Daniela N., Pagnotti, Gabriel M., Mohammad, Khalid S., Guise, Theresa A., Windle, Jolene J., David Roodman, G., Kurihara, Noriyoshi

“…Paget's disease (PD) is characterized by increased numbers of abnormal osteoclasts (OCLs) that drive exuberant bone formation, but the mechanisms responsible…”
Get full text

Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction by Storti, P, Bolzoni, M, Donofrio, G, Airoldi, I, Guasco, D, Toscani, D, Martella, E, Lazzaretti, M, Mancini, C, Agnelli, L, Patrene, K, Maïga, S, Franceschi, V, Colla, S, Anderson, J, Neri, A, Amiot, M, Aversa, F, David Roodman, G, Giuliani, N

“…Hypoxia-inducible transcription factor-1 (HIF-1α) is overexpressed in multiple myeloma (MM) cells within the hypoxic microenvironment. Herein, we explored the…”
Get full text

Targeting Notch Inhibitors to the Myeloma Bone Marrow Niche Decreases Tumor Growth and Bone Destruction without Gut Toxicity by Sabol, Hayley M, Ferrari, Adam J, Adhikari, Manish, Amorim, Tânia, McAndrews, Kevin, Anderson, Judith, Vigolo, Michele, Lehal, Rajwinder, Cregor, Meloney, Khan, Sharmin, Cuevas, Pedro L, Helms, Jill A, Kurihara, Noriyoshi, Srinivasan, Venkat, Ebetino, Frank H, Boeckman, Jr, Robert K, Roodman, G David, Bellido, Teresita, Delgado-Calle, Jesus

“…Systemic inhibition of Notch with γ-secretase inhibitors (GSI) decreases multiple myeloma tumor growth, but the clinical use of GSI is limited due to its…”
Get full text

Expression of XBP1s in bone marrow stromal cells is critical for myeloma cell growth and osteoclast formation by Xu, Guoshuang, Liu, Kai, Anderson, Judy, Patrene, Kenneth, Lentzsch, Suzanne, Roodman, G. David, Ouyang, Hongjiao

“…BM stromal cells (BMSCs) are key players in the microenvironmental support of multiple myeloma (MM) cell growth and bone destruction. A spliced form of the…”
Get full text

Osteocyte Vegf-a contributes to myeloma-associated angiogenesis and is regulated by Fgf23 by Mulcrone, Patrick L., Edwards, Shanique K. E., Petrusca, Daniela N., Haneline, Laura S., Delgado-Calle, Jesús, Roodman, G. David

“…Multiple Myeloma (MM) induces bone destruction, decreases bone formation, and increases marrow angiogenesis in patients. We reported that osteocytes (Ocys)…”
Get full text

Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma by Silbermann, R, Bolzoni, M, Storti, P, Guasco, D, Bonomini, S, Zhou, D, Wu, J, Anderson, J L, Windle, J J, Aversa, F, David Roodman, G, Giuliani, N

Get full text

Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction by Sabol, Hayley M., Amorim, Tânia, Ashby, Cody, Halladay, David, Anderson, Judith, Cregor, Meloney, Sweet, Megan, Nookaew, Intawat, Kurihara, Noriyoshi, Roodman, G. David, Bellido, Teresita, Delgado-Calle, Jesus

“…•Notch3 promotes proliferation and enhances the osteoclastogenic potential of multiple myeloma cells.•Notch3 mediates the communication between myeloma cells…”
Get full text

American Society of Clinical Oncology 2007 Clinical Practice Guideline Update on the Role of Bisphosphonates in Multiple Myeloma by KYLE, Robert A, YEE, Gary C, SOMERFIELD, Mark R, FLYNN, Patrick J, HALABI, Susan, JAGANNATH, Sundar, ORLOWSKI, Robert Z, ROODMAN, David G, TWILDE, Patricia, ANDERSON, Kenneth

“…To update the recommendations for the use of bisphosphonates in the prevention and treatment of bone disease in multiple myeloma. The Update Committee expanded…”
Get full text

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG by Hadji, Peyman, Aapro, Matti S., Body, Jean-Jacques, Gnant, Michael, Brandi, Maria Luisa, Reginster, Jean Yves, Zillikens, M. Carola, Glüer, Claus-C., de Villiers, Tobie, Baber, Rod, Roodman, G. David, Cooper, Cyrus, Langdahl, Bente, Palacios, Santiago, Kanis, John, Al-Daghri, Nasser, Nogues, Xavier, Eriksen, Erik Fink, Kurth, Andreas, Rizzoli, Rene, Coleman, Robert E.

“…Several guidelines have been reported for bone-directed treatment in women with early breast cancer (EBC) for averting fractures, particularly during aromatase…”
Get full text

Pharmacologic targeting of the p62 ZZ domain enhances both anti-tumor and bone-anabolic effects of bortezomib in multiple myeloma by Marino, Silvia, Petrusca, Daniela N, Bishop, Ryan T, Anderson, Judith L, Sabol, Hayley M, Ashby, Cody, Layer, Justin H, Cesarano, Annamaria, Davé, Utpal P, Perna, Fabiana, Delgado-Calle, Jesus, Chirgwin, John M, Roodman, G David

“…Multiple myeloma (MM) is a malignancy of plasma cells whose antibody secretion creates proteotoxic stress relieved by the N-end rule pathway, a proteolytic…”
Get full text

Role of osteocytes in multiple myeloma bone disease by Delgado-Calle, Jesus, Bellido, Teresita, Roodman, G. David

“…PURPOSE OF REVIEWDespite the increased knowledge of osteocyte biology, the contribution of this most abundant bone cell to the development and progression of…”
Get full text